The prognosis of pancreatic cancer is poor, the treatment is limited, and not many people can get accurate pathology, which leads to many patients dying with doubts. This is not only detrimental to the further study of pancreatic cancer, but also has a great negative influence on patients. Myth 1: Most pancreatic cancers do not live more than six months? In terms of growth pattern, foreign studies have shown that pancreatic cancer can be divided into “slow” and “fast” cancers, with “fast” cancers accounting for the majority of cases. According to the follow-up, as long as you actively cooperate with the treatment (especially pay attention to the lethal complications), even if you have “fast cancer”, you can extend your life for 1 to 2 years. As for “slow cancer”, most of them are benign or less malignant tumors of various special types of pancreatitis and slower growth rate (due to the lack of multidisciplinary consultation between imaging, pathology and clinical departments specializing in pancreatic research, many so-called “slow cancer” cases are misdiagnosed). In this group of cases, accurate diagnosis and targeted therapeutic measures can lead to a better outcome for most patients. The current high short-term mortality rate is not unrelated to the high psychological burden of patients and the operational level of doctors. Myth 2 Significantly elevated CA19-9 suggests pancreatic cancer? CA19-9 can be elevated to varying degrees in the presence of infections and neoplastic lesions of the biliary system and pancreas (most reports in the literature do not exceed 100). However, when it comes to differentiating pancreatic cancer from difficult or rare pancreatitis, it is often difficult to make up one’s mind. Myth 3: Involvement of large blood vessels around the pancreas means that pancreatic cancer cannot be removed? The posterior part of the pancreas has a complex structure with a narrow gap and dense distribution of blood vessels and nerves. There are not only tumors, but also inflammation, retroperitoneal fibrosis and many other diseases occurring in this area. The vascular changes include cancer thrombus, thrombosis, vasculitis, vascular occlusion, vascular stenosis, etc. Careful analysis of the morphology, intensification characteristics, medical history and follow-up changes of its vascular involvement and perivascular lesions can more or less identify some points of differentiation. Myth 4 Persistent low back pain is a clinical manifestation of end-stage pancreatic cancer? It is true that “lumbar back pain” is a clinical manifestation of retroperitoneal plexus involvement, but it is not exclusive to pancreatic cancer. It is also seen in retroperitoneal pseudocysts, retroperitoneal fibrosis, retroperitoneal chronic hematoma and infection caused by pancreatitis, surgery and trauma, etc. These diseases can be distinguished from pancreatic cancer metastases if their CT and MRI features are carefully analyzed: retroperitoneal fibrosis is lamellar and wraps around large blood vessels, dynamic enhancement scan shows delayed enhancement, and after several months of follow-up, it does not have the biological behavior of pancreatic cancer with rapid enlargement. .